A detailed history of Hrt Financial LP transactions in Xenon Pharmaceuticals Inc. stock. As of the latest transaction made, Hrt Financial LP holds 29,641 shares of XENE stock, worth $1.14 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
29,641
Previous 34,192 13.31%
Holding current value
$1.14 Million
Previous $1.33 Million 12.53%
% of portfolio
0.01%
Previous 0.01%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

SELL
$36.12 - $43.96 $164,382 - $200,061
-4,551 Reduced 13.31%
29,641 $1.17 Million
Q2 2024

Aug 12, 2024

BUY
$36.25 - $43.75 $57,420 - $69,300
1,584 Added 4.86%
34,192 $1.33 Million
Q1 2024

May 13, 2024

SELL
$42.66 - $50.04 $2.15 Million - $2.53 Million
-50,461 Reduced 60.75%
32,608 $1.4 Million
Q4 2023

Feb 09, 2024

BUY
$28.7 - $46.46 $1.37 Million - $2.22 Million
47,859 Added 135.92%
83,069 $3.83 Million
Q3 2023

Nov 13, 2023

BUY
$34.16 - $39.73 $589,738 - $685,898
17,264 Added 96.2%
35,210 $1.2 Million
Q2 2023

Aug 11, 2023

BUY
$34.84 - $43.54 $625,238 - $781,368
17,946 New
17,946 $690,000
Q3 2022

Nov 14, 2022

SELL
$30.79 - $39.82 $122,390 - $158,284
-3,975 Reduced 19.97%
15,927 $574,000
Q2 2022

Aug 12, 2022

BUY
$25.44 - $35.16 $506,306 - $699,754
19,902 New
19,902 $605,000
Q4 2021

Feb 14, 2022

SELL
$15.6 - $35.4 $161,569 - $366,637
-10,357 Closed
0 $0
Q3 2021

Nov 15, 2021

SELL
$14.86 - $19.45 $123,293 - $161,376
-8,297 Reduced 44.48%
10,357 $158,000
Q2 2021

Aug 16, 2021

SELL
$16.81 - $20.0 $37,385 - $44,480
-2,224 Reduced 10.65%
18,654 $347,000
Q1 2021

May 17, 2021

BUY
$13.65 - $21.31 $284,984 - $444,910
20,878 New
20,878 $373,000
Q1 2020

May 15, 2020

SELL
$8.08 - $17.57 $147,217 - $320,125
-18,220 Closed
0 $0
Q4 2019

Feb 14, 2020

BUY
$8.11 - $14.65 $147,764 - $266,923
18,220 New
18,220 $238,000

Others Institutions Holding XENE

About Xenon Pharmaceuticals Inc.


  • Ticker XENE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 62,263,500
  • Market Cap $2.39B
  • Description
  • Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, A Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epilepsy encephalopath...
More about XENE
Track This Portfolio

Track Hrt Financial LP Portfolio

Follow Hrt Financial LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Hrt Financial LP, based on Form 13F filings with the SEC.

News

Stay updated on Hrt Financial LP with notifications on news.